Key result
Spironolactone treatment in women older than 55 years did not increase the incidence of breast cancer compared to unexposed controls (HR 0.99; 95% CI 0.87-1.12).
Why the study?
Does spironolactone treatment increase the risk of incident breast cancer in women older than 55 years?
Population
83,993 female patients older than 55 years with no history of breast cancer, from 557 general practices in…
Comparison
Spironolactone vs Unexposed female controls, matched 2:1 by…
Design
Cohort
Follow-up
mean 4.1 years
Authors
Loading...
Supports spironolactone safety on breast cancer risk in older women; leaves open confirmation in randomized cardiovascular trials.
Cohort (n=1,290,625)
Yes
Does spironolactone treatment increase the risk of incident breast cancer in women older than 55 years?
Effect estimate: HR 0.99 (95% CI 0.87-1.12)
Absolute Event Rate: 0.39% vs 0.38%
Long-term use of spironolactone for cardiovascular conditions does not increase the risk of incident breast cancer in women older than 55 years.
Mackenzie et al. (2012) conducted a cohort in General population (n=1,290,625). Spironolactone vs. Unexposed controls was evaluated on New cases of breast cancer (HR 0.99, 95% CI 0.87-1.12). Spironolactone treatment in women older than 55 years did not increase the incidence of breast cancer compared to unexposed controls (HR 0.99; 95% CI 0.87-1.12).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: